Prurigo Nodularis (PN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Prurigo Nodularis Emerging Therapy and TPP Insights

Thelansis’s “Prurigo Nodularis (PN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Prurigo Nodularis Overview

Prurigo nodularis (PN) is a chronic neuroimmune skin disorder characterized by intensely pruritic, firm nodules and an itch-scratch cycle that can cause excoriation, pain, sleep disturbance, and quality-of-life impairment. Its pathobiology involves interactions among sensory nerves, keratinocytes, and immune pathways, particularly IL-4/IL-13 and IL-31 signaling. Management is multimodal and may include topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic therapy for extensive disease. Dupilumab, an IL-4 receptor alpha antagonist, and nemolizumab, an IL-31 receptor antagonist, are FDA-approved for adults with PN, demonstrating the value of targeted neuroimmune modulation. Current development is exploring additional cytokine, JAK and neural pathways to address inadequate response, treatment limitations, and disease heterogeneity. Key unmet needs include durable control of itch and lesions, treatment sequencing, and effective options for refractory disease globally.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)